Showing 311-320 of 8350 results for "".
Part 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benColloidal Oatmeal in the Treatment of Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/colloidal-oatmeal-in-the-treatment-of-atopic-dermatitis/23338/Is this plant-based intervention an effective treatment alternative?Tazarotene Lotion for Acne
https://practicaldermatology.com/topics/acne-rosacea/tazarotene-lotion-for-acne/23388/Tazarotene Lotion 0.045% offers dermatologists a new option that is effective and well tolerated for treating acne.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Embrace Your Curiosity: The Power of Questions
https://practicaldermatology.com/topics/practice-management/embrace-your-curiosity-the-power-of-questions/24031/Asking empowering questions may yield more creative answers.How Early Experience With PDT Can Provide Career Pathways
https://practicaldermatology.com/series/pdt-in-practice/how-early-experience-with-pdt-can-provide-career-pathways/20212/Adam Friedman, MD, professor and chair of dermatology at George Washington University, discusses how early-career experience with photodynamic therapy, including exposure to doctor-mentors in the field, gave him professional skills and connections that prepared him for later-career opportunities.Considering a Role for Oral JAK Inhibitors in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/considering-a-role-for-oral-jak-inhibitors-in-ad-care/23745/The newest class of treatments for AD expands the possibilities to achieve and maintain skin clearance.EBD Insights
https://practicaldermatology.com/conferences/maui-derm-2022/ebd-insights/20049/There are a number of new and reliable energy-based devices available. Michael H. Gold, MD discusses tried-and-true technologies as well as new and innovative devices that offer efficacious options on the market for a variety of dermatologic needs.DermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for Tre